B002 in Patients With HER2-positive Breast Cancer

Clinical trial NCT04382352 · COMPLETED

Trial details

NCT number: NCT04382352
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Breast Cancer Metastatic Breast Cancer

Start date: 2019-05-28
Primary completion: 2022-04-26
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.